Supply Resilience and Lessons Learned from the Pandemic

In this presentation we will share how the Biopharmaceutical Manufacturing Industry is evolving an approach to Supply Resilience based on lessons learned from the Pandemic, the desire of Senior Executives to focus on Supply Resilience in the post-pandemic era, and the need to develop industry-wide solutions that cover how we collaborate across the End-To-End Supply Chain to become aware of and respond to any future Crisis (not just the next Pandemic) that might impact our ability to supply biopharmaceuticals to the people that need them at country, region or global level. We will walk through a Pandemic Timeline activity undertaken in the early summer of 2023, explain how that was communicated to Industry Senior Sponsors, and how we have developed the terms of reference for a Crisis Response and Management Team. More specifically activities that underpin and support the Crisis Response & Management Team approach - such as pre-qualification of suppliers, criticality mapping (supply chain risk), Materials of Concern - Alert Process Looking to the future we are engaging effective  Stakeholder engagement across Agencies and external organizations such as BARDA, HERA, FDA, EMA   to develop a Supply Resilience Ethos across the End to End Supply Chain.